Paclitaxel and carboplatin in the treatment of advanced or recurrent endometrial cancer: A large retrospective study Journal Article


Authors: Sovak, M. A.; Dupont, J.; Hensley, M. L.; Ishill, N.; Gerst, S.; Abu Rustum, N.; Anderson, S.; Barakat, R.; Konner, J.; Poynor, E.; Sabbatini, P.; Spriggs, D. R.; Aghajanian, C.
Article Title: Paclitaxel and carboplatin in the treatment of advanced or recurrent endometrial cancer: A large retrospective study
Abstract: The aim of this study was to assess the efficacy and tolerability of paclitaxel and carboplatin (TC) in the treatment of patients with advanced or recurrent endometrial cancer. Patients eligible for this retrospective analysis had endometrial cancer with either advanced or recurrent measurable disease (untreated primary stage III/IV or stage III/IV patients with persistent, measurable disease [≥2 cm] after surgery), Eastern Cooperative Oncology Group (ECOG) performance status ≥3, and received at least one cycle of TC. Response rates were determined using Response Evaluation Criteria in Solid Tumors criteria. Institutional Review Board approval was obtained prior to the initiation of this study. Eighty-five eligible patients, with a median age of 62 years (range 36-80) were identified. Fifty-seven (67%) of patients were treated at the time of recurrence. Prior radiation therapy had been used in the treatment of 36 (42%) patients, while 13 (15%) patients had received prior chemotherapy. Median follow-up time was 11.7 months (range 1.1-96.7 months), and the median number of cycles of therapy received was six (range 1-18). The overall response rate (ORR) was 43%, with a complete response rate of 5% and a partial response rate of 38%. Chemotherapy-naive patients had an ORR of 47%. Only seven (8%) patients had to discontinue therapy due to toxicity. Median progression-free survival was 5.3 months (95% CI, 4.6-7.4), with a median overall survival of 13.2 months (95% CI, 11.7-18.2). We conclude that TC is an active and tolerable regimen in the treatment of patients with advanced or recurrent endometrial cancer. © 2007, IGCS and ESGO.
Keywords: adult; cancer chemotherapy; cancer survival; human tissue; aged; middle aged; cancer surgery; retrospective studies; human cell; major clinical study; overall survival; drug tolerability; cancer recurrence; advanced cancer; drug dose reduction; drug efficacy; drug withdrawal; paclitaxel; cancer patient; cancer radiotherapy; cancer staging; neurotoxicity; recurrent cancer; follow up; endometrial cancer; endometrial neoplasms; neoplasm staging; endometrium cancer; carboplatin; multiple cycle treatment; neoplasm recurrence, local; antineoplastic combined chemotherapy protocols; oncology; retrospective study; docetaxel; confidence interval; standard; evaluation; drug substitution; hypersensitivity reaction; institutional review; advanced disease; solid tumor criteria
Journal Title: International Journal of Gynecological Cancer
Volume: 17
Issue: 1
ISSN: 1048-891X
Publisher: Lippincott Williams & Wilkins  
Date Published: 2007-01-01
Start Page: 197
End Page: 203
Language: English
DOI: 10.1111/j.1525-1438.2006.00746.x
PUBMED: 17291253
PROVIDER: scopus
DOI/URL:
Notes: --- - "Cited By (since 1996): 15" - "Export Date: 17 November 2011" - "CODEN: IJGCE" - "Source: Scopus"
Altmetric Score
MSK Authors
  1. Mika Adachi Sovak
    6 Sovak
  2. Richard R Barakat
    597 Barakat
  3. Elizabeth Poynor
    31 Poynor
  4. Jakob Dupont
    64 Dupont
  5. Jason Konner
    85 Konner
  6. Paul J Sabbatini
    201 Sabbatini
  7. Scott R Gerst
    42 Gerst
  8. Martee L Hensley
    220 Hensley
  9. David R Spriggs
    314 Spriggs
  10. Nicole Marie Leoce
    86 Leoce